Touchlight announces today that Karen Fallen is stepping down as CEO & that Will Downie has been appointed Interim Chief Executive Officer. We thank Karen for her leadership, guidance and contributions to the building of Touchlight's CDMO business. eu1.hubs.ly/H0zfS_20

In a client study, Touchlight’s z- dbDNA™ generated 2× the mRNA yield of pDNA using copy-matched template amounts, delivering reduced dsRNA & comparable potency. Read the blog to learn how enzymatically produced cell-free DNA can help increase efficiency: eu1.hubs.ly/H0zf7WV0

Don't miss @PharmaronBio BioInnovate webinar on scaling AAV processes for advanced gene therapies. Peter Archibald, will share how dbDNA™ can increase AAV genome titres, improve full capsid percentages and reduce impurity packaging. Register here: eu1.hubs.ly/H0zb-bB0

Visit us at booth #11 at #ESGCT2026 & meet our team. Learn more about our cell-free DNA technology and how we’re advancing DNA manufacturing for next-generation therapies. Showcasing three scientific posters. Schedule a meeting today. 🔗 eu1.hubs.ly/H0z690n0 #ESGCTHamburg2026

Touchlight has won the Innovation Catalyst Award at #CPHIMilan! This recognition celebrates the innovation at the heart of what we do and the continued work of our team to advance DNA manufacturing and enable the next generation of genetic medicines. eu1.hubs.ly/H0yWGhX0

Heading to #BioJapan , find us at Booth# D-42. Our team will be on the ground, ready to talk cell-free DNA, from accelerating development timelines to scalable, high-purity DNA for next-gen gene therapies and vaccines. Schedule a meeting with our team: eu1.hubs.ly/H0yW6Nr0

Touchlight has won the CPHI Pharma Award for: Innovation Catalyst! Board member Will Downie accepted the award on our behalf. Congrats to all the award winners in 2026. eu1.hubs.ly/H0yVgn-0 #CPHIMilan #CPHIMilan2026 #PharmaAwards

As AAV therapies move toward commercial scale, DNA choice is becoming a manufacturing decision—not just a technical one. Discover why developers are rethinking DNA inputs to reduce process burden and improve scalability. eu1.hubs.ly/H0yV5CD0

Day 1 at Meeting on the Mesa is underway in Arizona🌵! We are all set up and ready to chat at Booth #M20. Stop by to learn how cell-free DNA technology is enabling faster, more flexible DNA supply for cell and gene therapy development. #MeetingOnTheMesa #CGMesa26

The Touchlight team will be at #CGMesa26 discussing how cell-free DNA technology is enabling faster, more flexible DNA supply for cell and gene therapy development. Book a meeting or stop by our booth M20. eu1.hubs.ly/H0yK5Jd0

Headed to #BioJapan2026? Find us at Booth D-42. Our team will be onsite & ready to talk cell-free DNA, from accelerating development timelines to scalable, high-purity DNA for next-gen gene therapies. Let's connect — schedule a meeting with our team: eu1.hubs.ly/H0yFZtM0

If you're working on next-gen cell therapies for inherited hematopoietic diseases, discover how we are enabling highly efficient, non-viral HDR in primary human CD34⁺ HSPCs, with knock-in efficiencies superior to #AAV and plasmid DNA. Access it here: eu1.hubs.ly/H0yCLSq0

The Touchlight team will be at #CGMesa26 discussing how cell-free DNA technology is enabling faster, more flexible DNA supply for cell and gene therapy development. Book a meeting or stop by our booth M20. eu1.hubs.ly/H0yyft70

Having issues with editing efficiency, long-term reconstitution & stem cell integrity in your HSC workflows? The choice of payload matters, with mbDNA achieving better engraftment in vivo following transplant. See the data in this on-demand webinar. eu1.hubs.ly/H0ypYR-0

Plasmid DNA has long been central to cell and gene therapy development. As manufacturing demands scale, many developers are re‑evaluating whether pDNA is still the best fit for speed, consistency, and long‑term resilience. Get insights in this Q&A article eu1.hubs.ly/H0ymkVV0

This application note shows how to achieve comparable RNA yields using approximately half the template mass of plasmid DNA, while maintaining key RNA quality attributes. Same #RNA yield, half the template input. 📥 Explore the data: eu1.hubs.ly/H0ykHdF0

The DNA debate isn't over; it's evolving. As gene therapies scale, developers are rethinking DNA supply chains to improve reliability, scalability, and manufacturing readiness. Catch up with this short 10-minute fireside chat on why and how. eu1.hubs.ly/H0yj9Nc0

The Touchlight team will be at #CGMesa26 discussing how cell-free DNA technology is enabling faster, more flexible DNA supply for cell and gene therapy development. Book a meeting or stop by our booth M20. eu1.hubs.ly/H0ydkX00

The BBC recently reported on a lung cancer patient receiving a new cancer vaccine, highlighting the potential of personalized immunotherapies. Touchlight's Doggybone™ DNA (dbDNA™) technology was used in the creation of this vaccine. Full story here: eu1.hubs.ly/H0yb-880?

This On-Demand Webinar presents how Touchlight & ElevateBio are enabling safer & more effective Cell and Gene Therapies. Empower efficient, targeted genome editing for your gene therapies. Watch it now: eu1.hubs.ly/H0y98rX0 #plasmiddna #syntheticdna #cellfreedna